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Objectives This study investigated the occurrence of intraluminal thrombus and its potential implications with facilitated
percutaneous coronary interventions (fPCIs).
Background The effect of fPCI on the presence and consequences of intraluminal thrombus is unknown.
Methods Thrombolysis In Myocardial Infarction (TIMI) flow grade, frame count, and thrombus grade; distal embolization;
and slow flow in the infarct-related artery were assessed in a blinded fashion on coronary angiograms in 1,342
patients from the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy With Per-
cutaneous Coronary Intervention) trial. Residual TIMI thrombus grade 2 and/or distal embolization and/or slow
flow, reflecting thrombus burden (TB), following PCI were correlated with ST-segment resolution, epicardial blood
flow, and clinical outcome. The clinical composite endpoint was death, congestive heart failure, or shock.
Results In the fPCI group, more TIMI flow grade 2/3 in the infarct-related artery at the first angiogram (73.7% vs. 33.4%,
p  0.001) and a higher TB following PCI (19.7% vs. 13.4%, p  0.002) were found in comparison with the pri-
mary PCI group. Post-PCI TIMI thrombus grade was significantly associated with ST-segment resolution (p 
0.001) and TIMI frame count (p  0.0001) in both groups. In the fPCI group, the presence of post-PCI thrombus
was associated with a significantly worse outcome at 90 days (clinical composite endpoint: 32.1% vs. 18.6%,
p  0.023). Multivariable logistic regression showed that facilitation with tenecteplase (p  0.005) and TB (odds
ratio: 2.43, 95% confidence interval: 1.30 to 4.51, p  0.0052) were independent predictors of 90-day mortality.
Conclusions In ASSENT-4 PCI, despite more patency, residual TB was significantly higher in fPCI patients and was associated
with less efficient tissue reperfusion and worse clinical outcomes. (A Trial Evaluating the Efficacy and Safety of
Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention [PCI] as
Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction [ASSENT-4 PCI]; NCT00168792)
(J Am Coll Cardiol 2011;57:1867–73) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.061Primary percutaneous coronary intervention (pPCI) is the
most effective reperfusion therapy (1) in patients with
ST-segment elevation myocardial infarction (STEMI) but
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Thrombus Burden During Facilitated Versus Primary PCI May 10, 2011:1867–73and has been compared with pPCI
in a number of trials. Neither fa-
cilitation with full-dose lytics, gly-
coprotein (GP) IIb/IIIa inhibitors,
or both (3) improved clinical out-
comes despite achieving higher
patency rates documented by an-
giography. The reasons for this
unexpected failure of fPCI remain
unknown. It has been hypothe-
sized that the performance of a
percutaneous coronary interven-
tion (PCI) in a prothrombotic en-
vironment created by lytic therapy
might be responsible for throm-
botic complications and, therefore,
a worse clinical outcome (4).
Whether lytic therapy and/or GP
IIb/IIIa antagonists given before
PCI significantly reduce the
amount of thrombus is unknown.
However, thrombi are associated
with a high risk of distal emboli-
zation (DE), microvascular ob-
struction, and suboptimal myocar-
dial reperfusion; therefore, they
potentially mediate an unfavorable clinical outcome in STEMI
patients (5-7). If fibrinolytic agents and/or GP IIb/IIIa antag-
onists indeed reduce the thrombus burden (TB), other mech-
anisms must be responsible for the unfavorable clinical
outcomes.
See page 1874
We performed a blinded, detailed analysis of the coronary
angiograms obtained in the ASSENT-4 PCI (Assessment
of the Safety and Efficacy of a New Treatment Strategy
With Percutaneous Coronary Intervention) study. We
wanted to relate infarct-related thrombus burden with
reperfusion efficiency and clinical outcomes in patients
randomized to fPCI versus pPCI.
Methods
Details of the ASSENT-4 PCI trial have been published
previously (8). Of the 1,667 patients enrolled, the angio-
grams of 1,431 patients were sent to the core angiography
laboratory in Leuven. Of these, 89 were of insufficient
quality to allow quantitative analyses. Therefore, the present
substudy is limited to 1,342 patients with analyzable angio-
grams, all of whom had 90-day follow-up. Among these,
656 had been assigned to fPCI and 686 to pPCI.
Angiographic analysis. All angiograms were assessed cen-
trally without knowledge of the treatment assignment. Angio-
grams were analyzed for the determination of the infarct-
related artery (IRA), the presence and size of the intraluminal
thrombus, epicardial blood flow, DE, collateral blood flow, and
Abbreviations
and Acronyms
CCE  clinical composite
endpoint
DE  distal embolization
fPCI  facilitated
percutaneous coronary
intervention
GP  glycoprotein
IRA  infarct-related artery
PCI  percutaneous
coronary intervention
pPCI  primary
percutaneous coronary
intervention
STEMI  ST-segment
elevation myocardial
infarction
STR  ST-segment
elevation resolution
TB  thrombus burden
TIMI  Thrombolysis In
Myocardial Infarction
TTG  TIMI thrombus
gradethe presence of a significant stenosis (50%) based on visual iinspection. Intracoronary thrombus was scored at baseline after
fibrinolytic therapy, during PCI (intraprocedural), and after
PCI (post-PCI) using the Thrombolysis InMyocardial Infarc-
tion (TIMI) thrombus grade (TTG) scoring system (9). The
equence with the largest thrombus during PCI was deter-
ined. Patency of the IRA and epicardial blood flow were
valuated by means of the TIMI flow grade scale (10) and
IMI frame count scale (11). We defined DE as a filling
efect with an abrupt cutoff in 1 or more coronary branches
istally to the culprit lesion. Slow epicardial blood flow was
etermined as a temporary or permanent decrease in the TIMI
ow grade scale of at least 1 grade after balloon inflation or
tent implantation without evidence of spasm or dissection.
resence of a residual thrombus (TTG2) after the procedure
r evidence of DE or slow flow during or immediately
ollowing the procedure was defined as a composite angio-
raphic endpoint. This endpoint was considered to be the
xpression of TB and was calculated only once.
lectrocardiographic analysis. The ST-segment elevation
esolution (STR) analysis performed in the ASSENT-4
CI trial has previously been described (12). Electrocardio-
rams were available for analysis in 981 (73.1%) patients at
0 min and in 1,090 (81.2%) patients at 180 min.
linical outcome. The clinical endpoints were pre-specified
n the protocol (8). The primary clinical composite endpoint
CCE) was a combination of death, congestive heart failure, or
hock 90 days after randomization. Congestive heart failure
nd shock were centrally adjudicated by a clinical event committee
naware of the allocated treatment. The definition of reinfarc-
ion was adopted from previous ASSENT trials (13).
tatistical analysis. Statistical analyses were performed with
AS (version 9.2, SAS Institute, Inc., Cary, North Carolina)
nd R (version 2.9, R Foundation for Statistical Computing,
ienna, Austria). Baseline characteristics and angiographic
esults were described by mean and SD or median and quartiles
Q1 and Q3) for continuous variables, and numbers and
ercentages for categorical variables. Between treatment
roups, comparisons were done by a t test, Wilcoxon rank sum
est, chi-square test, or Fisher exact test, as appropriate.
The relation between the presence of post-PCI thrombus
nd mortality, and CCE and reinfarction at day 90 for each
reatment group was verified by Fisher exact test.
Multivariable logistic regression analyses were used to
etermine independent correlates of residual thrombus,
CE, and 90-day mortality. To account for missing data in
he covariates, a multiple imputation strategy (5 imputa-
ions) was applied. First-order terms were forced into the
odel. Second-order interactions with treatment were ver-
fied. A significance level of 0.05 was applied without
orrection for multiple testing.
esults
aseline clinical characteristics are shown in Table 1.
ompared with the pPCI group, fPCI patients had a longer
edian time delay between randomization and first balloonnflation but not a significantly longer median time between
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May 10, 2011:1867–73 Thrombus Burden During Facilitated Versus Primary PCIBaseline Characteristics, Time Intervals, and TreatmentTable 1 Baseline Characteristics, Time Intervals, and Treatment
Facilitated PCI (n  656) Primary PCI (n  686) p Value
Age, yrs 60.8 12.3 59.9 11.9 0.181
Male 497/656 (75.8) 527/686 (76.8) 0.654
Actual or estimated weight, kg 78.0 14.5 77.8 15.0 0.866
Height, cm 170.5 8.3 169.8 8.3 0.168
Heart rate, beats/min 73.5 16.7 76.1 16.6 0.005
Systolic blood pressure, mm Hg 133.1 24.3 133.9 22.0 0.567
Killip class IV at randomization 7/656 (1.1) 7/683 (1.0) 0.999
Previous congestive heart failure 7/653 (1.1) 10/683 (1.5) 0.628
Previous myocardial infarction 85/652 (13.0) 66/683 (9.7) 0.057
Prior PCI 50/648 (7.7) 53/680 (7.8) 0.999
Prior CABG surgery 14/653 (2.1) 8/682 (1.2) 0.199
Diabetes mellitus 116/655 (17.7) 110/685 (16.1) 0.423
Hypertension 314/656 (47.9) 322/686 (46.9) 0.743
Chronic treatment with aspirin 140/654 (21.4) 118/683 (17.3) 0.061
Infarct location anterior 315/656 (48.0) 324/686 (47.2) 0.785
Time intervals
Symptoms onset to randomization, min 135.5 (90, 210) 135.0 (92, 208) 0.982
Symptoms onset to first balloon inflation, min 262.0 (210, 337) 255.0 (200, 331) 0.112
Randomization to first balloon inflation, min 114.0 (94, 148) 107.0 (85, 140) 0.001
Treatment before catheterization
Bolus of heparin given 613/650 (94.3) 646/681 (94.9) 0.999
Loading dose of clopidogrel or ticlopidine 39/653 (6.0) 41/684 (6.0) 0.999
Glycoprotein IIb/IIIa inhibitor 2/654 (0.3) 20/685 (2.9) 0.001
PCI performed 595/656 (90.7) 648/686 (94.5) 0.009
CABG performed during index hospitalization 26/654 (4.0) 17/685 (2.5) 0.125
Treatment during or after catheterization
Additional heparin 535/652 (82.1) 570/678 (84.1) 0.342
Loading dose of clopidogrel or ticlopidine 584/652 (89.6) 644/682 (94.4) 0.001
Glycoprotein IIb/IIIa inhibitor 93/651 (14.3) 374/679 (55.1) 0.001Data are mean  SD, n/N (%), or median (quartile 1, quartile 2).
CABG  coronary artery bypass grafting; PCI  percutaneous coronary intervention.Angiographic Characteristics and Reperfusion DataTable 2 Angiographic Characteristics and Reperfusion Data
Facilitated PCI (n  656) Primary PCI (n  686) p Value
Infarct-related artery 0.438
Left main coronary 4/656 (0.6) 2/686 (0.3)
Left anterior descending 285/656 (43.5) 308/686 (44.9)
Left circumflex artery 72/656 (11.0) 88/686 (12.8)
Right coronary artery 281/656 (42.8) 281/686 (41.0)
Saphenous vein graft 8/656 (1.2) 4/686 (0.6)
Coronary arteries without lesion 6/656 (0.9) 3/686 (0.4)
Multivessel disease 218/656 (33.2) 218/686 (31.8) 0.600
TIMI flow grade after fibrinolytic therapy 0.001
3 371/655 (56.6) 153/686 (22.3)
2 112/655 (17.1) 76/686 (11.1)
0/1 172/655 (26.3) 457/686 (66.6)
TIMI flow grade after PCI 0.333
3 500/588 (85.0) 562/642 (87.5)
2 59/588 (10.0) 58/642 (9.0)
0/1 29/588 (4.9) 22/642 (3.4)
Thrombectomy 19/574 (3.3) 41/625 (6.2) 0.021
Infarct-related artery stent implantation 539/585 (92.1) 602/638 (94.4) 0.14
Drug-eluting stent implantation 128/539 (23.8) 143/601 (23.8) 0.999Data are n (%).
PCI  percutaneous coronary intervention; TIMI  Thrombolysis In Myocardial Infarction.
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Thrombus Burden During Facilitated Versus Primary PCI May 10, 2011:1867–73symptom onset and first balloon inflation. Significantly
more patients underwent an intervention in the pPCI
group. A clopidogrel loading dose after the procedure and
GP IIb/IIIa inhibitors both before and after PCI were more
frequently administered to pPCI patients.
Significantly more patients in the fPCI group had an
open IRA on the first contrast injection (Table 2). Throm-
bus aspiration and PCI were performed more frequently in
patients assigned to pPCI. After PCI, the TIMI flow grade
rates were similar.
Clinical outcomes are shown in Table 3. The CCE and
reinfarction rates were higher in the fPCI group at both 30
and 90 days, and by 90 days there was also a tendency for
excess death, congestive heart failure, and shock in the fPCI
group.
Core laboratory angiographic measurements. After fi-
brinolytic therapy, significantly higher rates of TTG 0 to 3
were observed in the fPCI patients, and more frequent
TTG 5 was present in the pPCI patients (Fig. 1). During
the PCI procedure, more patent vessels without thrombus
were found in the fPCI patients, whereas more arteries with
medium-size thrombus (TTG 2/3) were present in pPCI
Clinical EndpointsTable 3 Clinical Endpoints
Facilitated PCI
(n  656)
Primary PCI
(n  686) p Value
30-day outcome
Death 36/656 (5.5) 23/685 (3.4) 0.063
Congestive heart failure 70/643 (10.9) 61/677 (9.0) 0.270
Shock 39/647 (6.0) 27/679 (4.0) 0.100
Clinical composite endpoint 107/645 (16.6) 81/679 (11.9) 0.018
Reinfarction 36/650 (5.5) 18/684 (2.6) 0.008
90-day outcome
Death 40/656 (6.1) 29/678 (4.2) 0.138
Congestive heart failure 76/643 (11.8) 63/676 (9.3) 0.151
Shock 41/643 (6.4) 27/675 (4.0) 0.061
Clinical composite endpoint 116/646 (18.0) 88/678 (13.0) 0.015
Reinfarction 42/644 (6.5) 22/677 (3.3) 0.007
Data are n (%).
PCI  percutaneous coronary intervention.
Core Laboratory Angiographic MeasurementsTable 4 Core Laboratory Angiographic Measurements
Facilitated PCI
(n  656)
Primary PCI
(n  686) p Value
Residual TIMI thrombus
grade 2
52/592 (8.8) 39/642 (6.1) 0.069
Slow flow 34/656 (5.2) 32/686 (4.7) 0.706
Distal embolization 55/656 (8.4) 39/686 (5.7) 0.055
Thrombus burden 129/656 (19.7) 92/686 (13.4) 0.002
Post-PCI TFC in relation to
post-PCI TTG (frame)
0.036
0 26 (16, 38.7) 26.7 (18, 40.0)
1 49.7 (26, 64) 40.1 (29.0, 67.5)
2 68.5 (41.8, 121.7) 46.0 (25.1, 59.2)
3–4 86.0 (38.4, 120.0) 14.0 (13.4, 92.0)
Data are n (%) or median (quartile 1, quartile 3).s
TFC  Thrombolysis In Myocardial Infarction frame count; TTG  Thrombolysis In Myocardial
Infarction thrombus grade; other abbreviations as in Tables 1 and 2.group. After the procedure, no statistically significant dif-
ferences in TTG were present. However, trends toward
more DE (p  0.055) and large (TTG 2) residual
hrombus (p 0.069) were observed in patients randomized
o fPCI. The calculated TB was significantly greater in
PCI patients (19.7% vs. 13.4%, p  0.002). The relation-
Figure 1 TTG After Fibrinolytic Therapy,
During PCI, and After PCI
Thrombolysis In Myocardial Infarction (TIMI) thrombus grade (TTG) after
fibrinolytic therapy, during percutaneous coronary intervention (PCI), and after PCI.hip between post-PCI TTG and TIMI frame counts was
di

t
l
i
i
S
s
[
1
7
(
T
C
c
t
s
t
a
w
d
s
t
p
D
C
w
e
p
i
t
m
p
p
r
1871JACC Vol. 57, No. 19, 2011 Zalewski et al.
May 10, 2011:1867–73 Thrombus Burden During Facilitated Versus Primary PCIsignificant in fPCI and pPCI patients (p  0.0001) but
ifferent between these 2 groups (p  0.036) (Table 4).
Using a multivariable logistic regression model, we found
ndependent pre-procedural determinants of large (TTG
2) residual thrombus following PCI: post-fibrinolytic
herapy TTG 3, no PCI, lack of stent implantation,
oading dose of clopidogrel/ticlopidine, tenecteplase admin-
Independent Determinants ofPresence of Residual Thrombus After PCITable 5 Independent Determinants ofPresence of Residual Thrombus After PCI
Residual TTG >2
Covariates OR 95% CI p Value
TTG 3 after fibrinolytic therapy 14.63 7.20–29.72 0.001
IRA stent implantation 0.001
No PCI vs. PCI with stent 17.33 1.73–174
PCI without stent vs. with stent 10.37 6.00–17.94
Loading dose of clopidogrel/ticlopidine
(yes vs. no)
0.35 0.18–0.67 0.0017
Assigned treatment (fPCI vs. pPCI) 1.93 1.19–3.14 0.0074
Time since symptoms onset to first
balloon (per 10 min)
1.03 1.01–1.05 0.0089
Age (per yr) 1.02 1.01–1.04 0.0089
Prior PCI (yes vs. no) 0.28 0.10–0.78 0.0147
Sex (male vs. female) 1.68 0.98–2.89 0.0607
Prior CABG (yes vs. no) 2.45 0.73–8.26 0.1477
TIMI flow before PCI (0/1 vs. 2/3) 0.71 0.42–1.19 0.1943
Right coronary artery (yes vs. no) 1.15 0.74–1.79 0.5381
Diabetes mellitus (yes vs. no) 1.16 0.74–2.00 0.5830
Multivessel disease (yes vs. no) 1.13 0.71–1.79 0.6059
Glycoprotein IIb/IIIa inhibitor (yes vs. no) 1.10 0.65–1.86 0.7193
Killip class 3/4 (yes vs. no) 1.24 0.34–4.50 0.7425
C-statistic  0.85.
CI  confidence interval; fPCI  facilitated percutaneous coronary intervention; IRA  infarct-
elated artery; OR  odds ratio; pPCI  primary percutaneous coronary intervention; other
abbreviations as in Tables 1, 2, and 4.
Multivariate Logistic Regression With Death and Clinical CompositTable 6 Multivariate Logistic Regression With Death and Clinic
Covariates
9
OR
Age (per yr) 1.10
Loading dose of clopidogrel/ticlopidine (yes vs. no) 0.23
Killip class 3/4 (yes vs. no) 6.12
Assigned treatment by sex interaction
fPCI vs. pPCI in women 5.31
fPCI vs. pPCI in men 0.85
Thrombus burden (yes vs. no) 2.43
Anterior infarct location (yes vs. no) 2.12
Glycoprotein IIb/IIIa inhibitor (yes vs. no) 1.99
Multivessel disease (yes vs. no) 1.61
Prior PCI (yes vs. no) 1.99
Prior CHF (yes vs. no) 2.88
Diabetes mellitus (yes vs. no) 1.38
Time since symptoms onset to first balloon (per 10 min) 0.99
TIMI flow grade before PCI (0/1 vs. 2/3) 1.19
Prior CABG (yes vs. no) 0.71C-statistic  0.89 and 0.78 for the 90-day mortality and CCE model, respectively.
CCE  clinical composite endpoint; CHF  congestive heart failure; other abbreviations as in Tables 1stration, age, time from onset of symptoms to first balloon
nflation, and lack of prior PCI (Table 5).
T-segment resolution. Patients assigned to fPCI had
ignificantly higher STR at 60 min (median [Q1, Q3]: 38.6%
0, 68.8] vs. 28.6% [–6.3, 58.1], p  0.002), whereas STR at
80 min was similar in the 2 groups (71.4% [47.9, 87.5] vs.
1.2% [50.0, 87.5], p 0.95). There was a strong relationship
p  0.0001) between post-fibrinolytic therapy and post-PCI
TGs and the amount of STR in both groups (Fig. 2).
linical outcomes versus thrombus burden. Clinical out-
omes analyzed according to the presence (or suspicion) of
hrombus (TTG 1 to 5) versus no thrombus (TTG 0) are
hown in Figure 3. Compared with the pPCI population, in
he fPCI group, post-PCI TTG 1 to 5 was associated with
significantly higher risk of CCE (p  0.023) and TTG 0
ith a higher risk of reinfarction (p  0.020).
Multivariable logistic regression showed that age, loading
ose of clopidogrel/ticlopidine, Killip class 3/4 on admis-
ion, facilitation with tenecteplase especially in women,
hrombus burden, and anterior wall infarction were inde-
endent correlates of the 90-day mortality (Table 6).
iscussion
linical trials have indicated that lytic-based fPCI is associated
ith more patent IRA immediately before PCI (3,8). How-
ver, this did not translate into a clinical benefit. Our study
rovides a possible explanation for this remarkable finding.
We evaluated the frequency and consequences of residual
ntracoronary thrombus following fibrinolysis versus no lytic
herapy and the amount of thrombus before and after
echanical fragmentation with PCI. An angiographic com-
osite endpoint consisting of residual thrombus after the
rocedure, slow flow, and distal embolization during and/or
point as a Dependent Variablemposite Endpoint as a Dependent Variable
Dependent Variable
Mortality 90-Day CCE
CI p Value OR 95% CI p Value
1.13 0.0001 1.05 1.04–1.07 0.001
0.47 0.0001 0.49 0.29–0.83 0.0085
16.3 0.0003 2.03 0.86–4.77 0.1063
0.0050 0.0060
16.7 3.12 1.65–5.89
1.88 1.13 0.72–1.78
4.51 0.0052 1.48 0.98–2.25 0.0625
3.79 0.0117 2.48 1.76–3.49 0.001
4.10 0.0604 1.09 0.72–1.63 0.6837
2.88 0.1056 1.66 1.17–2.35 0.0047
4.73 0.1200 1.32 0.74–2.35 0.3443
14.2 0.1925 6.05 1.97–18.6 0.0017
2.60 0.3209 1.22 0.82–1.83 0.3266
1.02 0.4504 1.01 0.99–1.02 0.4690
2.17 0.5725 1.38 0.96–1.98 0.0808
3.57 0.6766 0.91 0.32–2.61 0.8625e Endal Co
0-Day
95%
1.07–
0.11–
2.30–
1.69–
0.38–
1.30–
1.18–
0.97–
0.90–
0.84–
0.59–
0.73–
0.96–
0.65–
0.14–, 2, and 5.
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Thrombus Burden During Facilitated Versus Primary PCI May 10, 2011:1867–73immediately following the completion of the procedure was
prospectively defined.
As expected, fPCI was associated with less total IRA
occlusions but with more thrombus in the open vessels.
Although more clearance of thrombus from the epicardial
vessel was observed during the PCI procedure in the fPCI
arm, this was associated with a significantly higher TB.
The presence of thrombus was associated with less STR,
slower epicardial flow, and with a worse clinical outcome in
both groups, but more so in the fPCI patients. The latter
findings might be explained by the fact that a thrombus
resistant to fibrinolysis is more likely to cause distal obstruction
after subsequent fragmentation during PCI, and therefore
more likely to impair tissue reperfusion. We have found that a
longer time interval from symptom onset to first balloon
inflation is independently associated with a larger residual
thrombus. These findings are in agreement with the observa-
tion that intracoronary thrombi removed with distal protection
devices during primary PCI are more highly organized and rich
in fibrin in patients with later presentation (14). Consistent
with the results of previous studies (15), it was also found that
prior PCI decreases the amount of residual thrombus. Age,
loading with thienopyridine, cardiogenic shock or pulmonary
Figure 2 ST-Segment Resolution in Relation to TTG
Box plot shows median and interquartile range (IQR) (Q3 to Q1). Q1 and Q3 are th
Extreme values are omitted. Abbreviations as in Figure 1.edema at randomization, intracoronary TB, anterior infarction,and fPCI independently influenced 90-day mortality. Surpris-
ingly, the presence of residual intracoronary thrombus was not
associated with a statistically significantly higher risk of rein-
farction in both groups.
The well-known prothrombotic effects of fibrinolytic
agents (16), the suboptimal antithrombotic cotherapy in this
trial and, as a consequence, the presence of residual throm-
bus resistant to lytic therapy might be responsible for the
unexpected failure of facilitated PCI.
Study limitations. Our study has several limitations, the
most important being its retrospective nature. However, all
analyses were performed blinded to the allocated treatment.
Angiograms were available for analysis in only 81% of the
patients enrolled. However, baseline characteristics of this
subpopulation were similar to those of the total population.
Furthermore, activated clotting time values were not col-
lected, and the use of thrombus aspiration was lower than
would be expected today. Finally, grading the amount of
thrombus is to a certain extent subjective.
Conclusions
Our results indicate that with the antithrombotic cotherapy
and third quartiles. Whiskers are drawn at Q3  1.5  IQR, Q1 – 1.5  IQR.e firstgiven in ASSENT-4 PCI, pre-treatment with a full dose of a
1873JACC Vol. 57, No. 19, 2011 Zalewski et al.
May 10, 2011:1867–73 Thrombus Burden During Facilitated Versus Primary PCIfibrin-specific fibrinolytic agent does not decrease thrombotic
consequences in the immediate peri-PCI period and, in fact,
was associated with a greater TB, less favorable reperfusion,
Figure 3 90-Day Clinical Outcome in Relation to TTG
Graphs show 90-day clinical outcome in relation to TTG.
Abbreviations as in Figure 1.and a worse clinical outcome. These findings stress the impor-tance of optimal timing of PCI and of optimal antithrombotic
cotherapy after fibrinolysis for STEMI.
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